Immatics Aktie

8,08 EUR -0,46 EUR -5,39 %

18:18:13

STU

9,70 USD -0,58 USD -5,64 %

18:29:22

BTT

Immatics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.1,12 Mrd. EUR

KGV45,66Div. Rendite0,00%

WKNA2P72S

ISINNL0015285941

SymbolIMTX

Immatics Aktien News

Sortieren:Datum Meistgelesen

17.11.25ZacksImmatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates

13.08.25ZacksImmatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates

03.06.25ZacksDoes Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect?

WerbungImmatics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

31.05.25GlobeNewswireImmatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

13.05.25GlobeNewswireImmatics Announces First Quarter 2025 Financial Results and Business Update

23.04.25GlobeNewswireImmatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

27.03.25GlobeNewswireImmatics Announces Full Year 2024 Financial Results and Business Update

18.11.24GlobeNewswireImmatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

08.11.24GlobeNewswireImmatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

11.10.24GlobeNewswireImmatics Announces Pricing of $150 Million Public Offering

10.10.24GlobeNewswireImmatics Announces Proposed $150 Million Public Offering

10.10.24GlobeNewswireImmatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

04.10.24GlobeNewswireImmatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

16.09.24GlobeNewswireImmatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

06.09.24GlobeNewswireImmatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

13.08.24GlobeNewswireImmatics Announces Second Quarter 2024 Financial Results and Business Update

31.07.24GlobeNewswireImmatics Appoints Alise Reicin to Board of Directors

18.07.24GlobeNewswireImmatics Announces Upcoming Oral Presentation at ESMO Congress 2024

14.05.24GlobeNewswireImmatics Announces First Quarter 2024 Financial Results and Business Update

21.03.24GlobeNewswireImmatics Announces Full Year 2023 Financial Results and Corporate Update

18.01.24GlobeNewswireImmatics Announces Pricing of $175 Million Public Offering

17.01.24GlobeNewswireImmatics Announces Proposed Public Offering

16.01.24PR NewswireDISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

14.11.23GlobeNewswireImmatics Announces Third Quarter 2023 Financial Results and Business Update

08.11.23GlobeNewswireImmatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

24.10.23GlobeNewswireImmatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy

12.09.23PR NewswireProtalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

11.09.23GlobeNewswireModerna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

17.08.23GlobeNewswireImmatics Announces Second Quarter 2023 Financial Results and Business Update

10.08.23GlobeNewswireImmatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors

24.07.23GlobeNewswireImmatics Announces $35 Million Equity Investment from Bristol Myers Squibb

16.05.23GlobeNewswireImmatics Announces First Quarter 2023 Financial Results and Business Update

02.05.23GlobeNewswireImmatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME

01.05.23GlobeNewswireImmatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration

21.03.23GlobeNewswireImmatics Announces Full Year 2022 Financial Results and Corporate Update

Immatics News

Immatics News: auf dieser Seite finden Sie alle Immatics News und Nachrichten zur Immatics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Immatics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Immatics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.